Ameritox’s patented Rx Guardian methodology is said to be the only pain medication monitoring process that uses a patented methodology to help physicians assess whether patients are taking their pain medication consistent with the prescribed dosage.
Ameritox provides physicians and other prescribers with valuable information and a wide range of tools to help them better manage their patients’ chronic pain and to help mitigate risks associated with non-compliance, diversion and more.
Under the agreement, Ameritox will provide laboratory analyses for a broad range of drugs and metabolites using state-of-the-art equipment, such as multiplexing liquid chromatography-tandem mass spectrometry; the patented Rx Guardian methodology which compares expected ranges to a normalized value based upon each patient’s prescription regimen and other individual data; detailed Rx Guardian Reports that not only indicate in-range and out-of-range results, but also include a toxicologist’s explanation of the potential sources of detected compounds; and a toxicology hotline offering individual consultations to prescribers.